Skip to main content

Table 4 Dengue antibody GMTs and seropositivity status, in YF non-immune participants following CYD-TDV alone (Groups 1 and 2 pooled) or CYD-TDV co-administered with YF vaccine (Group 3)

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Time point Group 1 and 2 pooled, YF− (n = 116) Group 3, YF− (n = 108)
n GMT (95% CI) Seropositive, % (95% CI) n GMT (95% CI) Seropositive, % (95% CI)
Serotype 1
 Baseline 116 5.19 (4.87–5.53) 1.7 (0.2–6.1) 108 5.00 (NC) 0 (0.0–3.4)
 Post-dose 1 116 8.71 (7.04–10.8) 23.3 (15.9–32.0) 108 7.68 (6.46–9.14) 20.4 (13.2–29.2)
Serotype 2
 Baseline 116 5.06 (4.94–5.19) 0.9 (0.0–4.7) 108 5.06 (4.94–5.20) 0.9 (0.0–5.1)
 Post-dose 1 116 18.8 (13.9–25.3) 46.6 (37.2–56.0) 108 10.8 (8.63–13.4) 35.2 (26.2–45.0)
Serotype 3
 Baseline 116 5.21 (4.97–5.47) 2.6 (0.5–7.4) 108 5.28 (4.90–5.69) 2.8 (0.6–7.9)
 Post-dose 1 114 28.5 (20.4–39.7) 57.9 (48.3–67.1) 108 8.88 (7.23–10.9) 25.0 (17.2–34.3)
Serotype 4
 Baseline 116 5.43 (4.99–5.92) 3.4 (0.9–8.6) 108 5.26 (4.90–5.65) 1.9 (0.2–6.5)
 Post-dose 1 114 229 (139–378) 74.6 (65.6–82.3) 107 22.6 (15.9–32.3) 48.6 (38.8–58.5)
  1. YF seronegative participants at baseline are defined as those participants with YF baseline titre < 10 1/dil using PRNT80. Dengue seropositive defined as dengue antibody titres ≥10 (1/dil) against each serotype, and against at least 3 or all 4 serotypes with the parental dengue virus strain
  2. GMT geometric mean titre, n number of participants with available data for endpoint, YF yellow fever